Management of Chronic Liver Failure Until Liver Transplantation

Medical Clinics of North America

Volumn 92, Issue 4, 2008, Pages 839-860

  Arora, Gaurav ^a,b   Keeffe, Emmet B ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; FUROSEMIDE; LACTITOL; LACTULOSE; NORFLOXACIN; SPIRONOLACTONE;

ASCITES; BACTERIAL PERITONITIS; BILIARY CIRRHOSIS; CHRONIC LIVER DISEASE; COMPUTER ASSISTED TOMOGRAPHY; ESOPHAGUS VARICES; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; JAUNDICE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARACENTESIS; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PORTAL HYPERTENSION; PORTOPULMONARY HYPERTENSION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; WILSON DISEASE;

CHRONIC DISEASE; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; PROGNOSIS; TIME FACTORS;

EID: 44949135030     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2008.03.006     Document Type: Review

References (90)

1. Minino A.M., Heron M.P., and Smith B.L. Deaths: preliminary data for 2004. Natl Vital Stat Rep 54 19 (2006) 1-49
2. United Network for Organ Sharing. Available at:. http://www.unos.org Accessed September 24, 2007
3. United Network for Organ Sharing (UNOS). Donors and waiting list: 1993-2002 national data. Available at:. http://www.unos.org/data/ Accessed September 24, 2007
4. American Gastroenterological Association. The burden of gastrointestinal diseases. Available at:. http://www.gastro.org/user-assets/Documents/burden-report.pdf Accessed September 10, 2007
5. Malinchoc M., Kamath P.S., Gordon F.D., et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31 4 (2000) 864-871
6. Freeman Jr. R.B., Wiesner R.H., Harper A., et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 8 9 (2002) 851-858
7. Abdi W., Millan J.C., and Mezey E. Sampling variability on percutaneous liver biopsy. Arch Intern Med 139 6 (1979) 667-669
8. Runyon B.A. Management of adult patients with ascites caused by cirrhosis. Hepatology 27 1 (1998) 264-272
9. Gines P., Quintero E., Arroyo V., et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 7 1 (1987) 122-128
10. Arroyo V., Gines P., Gerbes A.L., et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 23 1 (1996) 164-176
11. Bories P., Garcia Compean D., Michel H., et al. The treatment of refractory ascites by the LeVeen shunt. A multi-centre controlled trial (57 patients). J Hepatol 3 2 (1986) 212-218
12. Schrier R.W., Arroyo V., Bernardi M., et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8 5 (1988) 1151-1157
13. Gines P., Fernandez-Esparrach G., Arroyo V., et al. Pathogenesis of ascites in cirrhosis. Semin Liver Dis 17 3 (1997) 175-189
14. Morali G.A., Sniderman K.W., Deitel K.M., et al. Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites?. J Hepatol 16 1-2 (1992) 249-250
15. Gines P., Tito L., Arroyo V., et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 94 6 (1988) 1493-1502
16. Runyon B.A. Refractory ascites. Semin Liver Dis 13 4 (1993) 343-351
17. Rossle M., Ochs A., Gulberg V., et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 342 23 (2000) 1701-1707
18. Gines P., Uriz J., Calahorra B., et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 123 6 (2002) 1839-1847
19. Salerno F., Merli M., Riggio O., et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 40 3 (2004) 629-635
20. Sanyal A.J., Genning C., Reddy K.R., et al. The North American study for the treatment of refractory ascites. Gastroenterology 124 3 (2003) 634-641
21. Salerno F., Camma C., Enea M., et al. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 133 3 (2007) 825-834
22. Kamath P.S., Wiesner R.H., Malinchoc M., et al. A model to predict survival in patients with end-stage liver disease. Hepatology 33 2 (2001) 464-470
23. Fernandez J., Navasa M., Gomez J., et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 35 1 (2002) 140-148
24. Runyon B.A. Monomicrobial nonneutrocytic bacterascites: a variant of spontaneous bacterial peritonitis. Hepatology 12 4 Pt 1 (1990) 710-715
25. Rimola A., Salmeron J.M., Clemente G., et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Hepatology 21 3 (1995) 674-679
26. McHutchison J.G., and Runyon B.A. Spontaneous bacterial peritonitis. In: Surawicz C.M., and Owen R.L. (Eds). Gastrointestinal and hepatic infections (1995), WB Saunders, Philadelphia 455-475
27. Angeli P., Guarda S., Fasolato S., et al. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther 23 1 (2006) 75-84
28. Sort P., Navasa M., Arroyo V., et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341 6 (1999) 403-409
29. Navasa M., Follo A., Llovet J.M., et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 111 4 (1996) 1011-1017
30. Toledo C., Salmeron J.M., Rimola A., et al. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 17 2 (1993) 251-257
31. Runyon B.A., McHutchison J.G., Antillon M.R., et al. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. Gastroenterology 100 6 (1991) 1737-1742
32. Follo A., Llovet J.M., Navasa M., et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 20 6 (1994) 1495-1501
33. Tito L., Rimola A., Gines P., et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 8 1 (1988) 27-31
34. Andreu M., Sola R., Sitges-Serra A., et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 104 4 (1993) 1133-1138
35. Soares-Weiser K., Brezis M., Tur-Kaspa R., et al. Antibiotic prophylaxis of bacterial infections in cirrhotic inpatients: a meta-analysis of randomized controlled trials. Scand J Gastroenterol 38 2 (2003) 193-200
36. Bernard B., Grange J.D., Khac E.N., et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 29 6 (1999) 1655-1661
37. Hou M.C., Lin H.C., Liu T.T., et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology 39 3 (2004) 746-753
38. Gines P., Rimola A., Planas R., et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 12 4 Pt 1 (1990) 716-724
39. Guarner C., Sola R., Soriano G., et al. Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels. Gastroenterology 117 2 (1999) 414-419
40. Rasaratnam B., Kaye D., Jennings G., et al. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med 139 3 (2003) 186-193
41. Fernandez J., Navasa M., Planas R., et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 133 3 (2007) 818-824
42. Ferenci P., Lockwood A., Mullen K., et al. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 35 3 (2002) 716-721
43. Prasad S., Dhiman R.K., Duseja A., et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 45 3 (2007) 549-559
44. Lizardi-Cervera J., Almeda P., Guevara L., et al. Hepatic encephalopathy: a review. Ann Hepatol 2 3 (2003) 122-130
45. Williams R., and Bass N. Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety. Rev Gastroenterol Disord 5 Suppl 1 (2005) S10-S18
46. Roberts L.R., and Kamath P.S. Pathophysiology and treatment of variceal hemorrhage. Mayo Clin Proc 71 10 (1996) 973-983
47. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. N Engl J Med 319 15 (1988) 983-989
48. D'Amico G., Pagliaro L., and Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 19 4 (1999) 475-505
49. Sarin S.K., Lamba G.S., Kumar M., et al. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 340 13 (1999) 988-993
50. Jutabha R., Jensen D.M., Martin P., et al. Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology 128 4 (2005) 870-881
51. Khuroo M.S., Khuroo N.S., Farahat K.L., et al. Meta-analysis: endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleeding. Aliment Pharmacol Ther 21 4 (2005) 347-361
52. Lui H.F., Stanley A.J., Forrest E.H., et al. Primary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate. Gastroenterology 123 3 (2002) 735-744
53. Imperiale T.F., and Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology 33 4 (2001) 802-807
54. Schepke M., Kleber G., Nurnberg D., et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 40 1 (2004) 65-72
55. Khan S., Tudur Smith C., Williamson P., et al. Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosis. Cochrane Database Syst Rev 4 (2006) CD000553
56. de la Pena J., Brullet E., Sanchez-Hernandez E., et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology 41 3 (2005) 572-578
57. Sarin S.K., Lahoti D., Saxena S.P., et al. Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology 16 6 (1992) 1343-1349
58. Barange K., Peron J.M., Imani K., et al. Transjugular intrahepatic portosystemic shunt in the treatment of refractory bleeding from ruptured gastric varices. Hepatology 30 5 (1999) 1139-1143
59. Chau T.N., Patch D., Chan Y.W., et al. "Salvage" transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. Gastroenterology 114 5 (1998) 981-987
60. Lo G.H., Liang H.L., Chen W.C., et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy 39 8 (2007) 679-685
61. Akriviadis E., Botla R., Briggs W., et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 119 6 (2000) 1637-1648
62. Gonwa T.A., Morris C.A., Goldstein R.M., et al. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome-experience in 300 patients. Transplantation 51 2 (1991) 428-430
63. Duvoux C., Zanditenas D., Hezode C., et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 36 2 (2002) 374-380
64. Fernandez J., Navasa M., Garcia-Pagan J.C., et al. Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. J Hepatol 41 3 (2004) 384-390
65. Moreau R., Durand F., Poynard T., et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 122 4 (2002) 923-930
66. Fabrizi F., Dixit V., and Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther 24 6 (2006) 935-944
67. Angeli P., Volpin R., Gerunda G., et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 29 6 (1999) 1690-1697
68. Brensing K.A., Textor J., Perz J., et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 47 2 (2000) 288-295
69. Guevara M., Gines P., Bandi J.C., et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 28 2 (1998) 416-422
70. Wong F., Pantea L., and Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 40 1 (2004) 55-64
71. Stoller J.K., Lange P.A., Westveer M.K., et al. Prevalence and reversibility of the hepatopulmonary syndrome after liver transplantation. The Cleveland Clinic experience. West J Med 163 2 (1995) 133-138
72. Hopkins W.E., Waggoner A.D., and Barzilai B. Frequency and significance of intrapulmonary right-to-left shunting in end-stage hepatic disease. Am J Cardiol 70 4 (1992) 516-519
73. Martinez G.P., Barbera J.A., Visa J., et al. Hepatopulmonary syndrome in candidates for liver transplantation. J Hepatol 34 5 (2001) 651-657
74. Rodriguez-Roisin R., Krowka M.J., Herve P., et al. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 24 5 (2004) 861-880
75. Schenk P., Schoniger-Hekele M., Fuhrmann V., et al. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology 125 4 (2003) 1042-1052
76. Henrion J., Schapira M., Luwaert R., et al. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine 82 6 (2003) 392-406
77. Colle I.O., Moreau R., Godinho E., et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 37 2 (2003) 401-409
78. Benjaminov F.S., Prentice M., Sniderman K.W., et al. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 52 9 (2003) 1355-1362
79. Kawut S.M., Taichman D.B., Ahya V.N., et al. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 11 9 (2005) 1107-1111
80. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 1 (2006) 65-73
81. Caballeria L., Pares A., Castells A., et al. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol 96 4 (2001) 1160-1163
82. Kobayashi M., Ikeda K., Hosaka T., et al. Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections. J Med Virol 78 4 (2006) 459-465
83. Elzouki A.N., and Eriksson S. Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma?. Eur J Gastroenterol Hepatol 8 10 (1996) 989-994
84. Hassan M.M., Hwang L.Y., Hatten C.J., et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36 5 (2002) 1206-1213
85. Hsing A.W., McLaughlin J.K., Olsen J.H., et al. Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer 60 2 (1995) 160-162
86. Bruix J., and Sherman M. Management of hepatocellular carcinoma. Hepatology 42 5 (2005) 1208-1236
87. Miller W.J., Baron R.L., Dodd G.D., et al. Malignancies in patients with cirrhosis: CT sensitivity and specificity in 200 consecutive transplant patients. Radiology 193 3 (1994) 645-650
88. Pugh R.N., Murray-Lyon I.M., Dawson J.L., et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60 8 (1973) 646-649
89. Lucey M.R., Brown K.A., Everson G.T., et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg 3 6 (1997) 628-637
90. Seaberg E.C., Belle S.H., Beringer K.C., et al. Liver transplantation in the United States from 1987-1998: updated results from the Pitt-UNOS liver transplant registry. In: Cecka J.M., and Terasaki P.I. (Eds). Clinical transplants 1998, vol. 14 (1999), UCLA Tissue Typing Laboratory, Los Angeles 17-37